Back

Notification report


Full notification file


General information

Notification Number
B/NL/17/005

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
05/07/2017

Title of the Project
A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non Hodgkin Lymphoma

Proposed period of release:
01/12/2017 to 31/12/2021

Name of the Institute(s) or Company(ies)
Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Austria; Belgium; Germany; Denmark; Spain; Finland; France; United Kingdom; Italy; Sweden; Norway;

Has the same GMO been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):


GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
JCAR017 is a second generation CAR T cell construct comprised of autologous CD4+ and CD8+ T cells expressing a CD19-specific CAR consisting of an scFv binding domain derived from the FMC63 murine CD19-specific mAb fused to the 4-1BB and CD3ΞΆ chain signaling domains.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HumanHomoSapiens---

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known